| Budget Amount *help |
¥19,110,000 (Direct Cost: ¥14,700,000、Indirect Cost: ¥4,410,000)
Fiscal Year 2012: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2011: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2010: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
|
|---|
| Research Abstract |
To predict the effect of anti-cancer drugs, such as gemcitabine in pancreatic cancer and biliary tract cancer, is also crucial to improve QOL of patients not only improve the survival rate. By combination of targeted proteomics and metabolomic analysese, we investigated the quantitation of membrane transporters and enzymes for drug metabolism using the biliary tract cancer and pancreatic cancer cell line. We found that reduced expression of deoxycitidine kinase (dCK) are brought anticancer drug resistance. Now, we are analyzing the surgical specimens of biliary tract cancer and pancreatic cancer and referring to clinical outcome.
|
